HRT Financial LLC bought a new stake in AbbVie Inc (NYSE:ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,566 shares of the company’s stock, valued at approximately $237,000.
Other large investors also recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in AbbVie by 3.2% during the second quarter. Morgan Stanley now owns 11,134,470 shares of the company’s stock worth $1,031,608,000 after purchasing an additional 348,882 shares in the last quarter. Janus Henderson Group PLC boosted its position in AbbVie by 15.9% during the second quarter. Janus Henderson Group PLC now owns 5,243,956 shares of the company’s stock worth $485,867,000 after purchasing an additional 717,452 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in AbbVie by 3.4% during the second quarter. Dimensional Fund Advisors LP now owns 4,824,617 shares of the company’s stock worth $447,001,000 after purchasing an additional 157,594 shares in the last quarter. Franklin Resources Inc. boosted its position in AbbVie by 8.5% during the first quarter. Franklin Resources Inc. now owns 4,359,665 shares of the company’s stock worth $412,643,000 after purchasing an additional 340,709 shares in the last quarter. Finally, Aristotle Capital Management LLC boosted its position in AbbVie by 0.9% during the first quarter. Aristotle Capital Management LLC now owns 3,787,873 shares of the company’s stock worth $358,522,000 after purchasing an additional 34,727 shares in the last quarter. 69.37% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have commented on ABBV. Credit Suisse Group set a $85.00 target price on AbbVie and gave the stock a “sell” rating in a research report on Saturday, October 20th. Bank of America decreased their target price on AbbVie from $112.00 to $105.00 and set a “buy” rating on the stock in a research report on Monday, July 30th. Cowen set a $110.00 target price on AbbVie and gave the stock a “buy” rating in a research report on Friday, July 27th. Zacks Investment Research downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Saturday, July 14th. Finally, BMO Capital Markets reiterated a “sell” rating and set a $78.00 target price on shares of AbbVie in a research report on Friday, July 27th. Six research analysts have rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. AbbVie has an average rating of “Hold” and a consensus price target of $105.68.
NYSE ABBV opened at $79.56 on Friday. AbbVie Inc has a fifty-two week low of $77.50 and a fifty-two week high of $125.86. The firm has a market capitalization of $117.89 billion, a PE ratio of 14.21, a P/E/G ratio of 0.77 and a beta of 1.62. The company has a quick ratio of 0.71, a current ratio of 0.80 and a debt-to-equity ratio of 8.70.
AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.13. AbbVie had a return on equity of 362.05% and a net margin of 20.84%. The company had revenue of $8.24 billion during the quarter, compared to analysts’ expectations of $8.23 billion. During the same period in the previous year, the firm posted $1.41 earnings per share. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, research analysts predict that AbbVie Inc will post 7.86 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Monday, October 15th will be issued a $0.96 dividend. The ex-dividend date of this dividend is Friday, October 12th. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.83%. AbbVie’s dividend payout ratio (DPR) is 68.57%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
See Also: What is the float in trading stocks?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.